Company intelligence / Profile preview

QBiotics Group Limited

Ownership: Private
Development stage: Phase 2

Overview

Lead oncology candidate tigilanol tiglate is in Phase II trials for soft tissue sarcoma and head and neck cancer. Has FDA Orphan Drug Designation for soft tissue sarcoma. Veterinary formulation STELFONTA® is commercially approved for canine mast cell tumors. Wound healing candidate EBC-1013 is entering Phase I trials.

Therapeutic areas: OncologyDermatologyInfectious Diseases
Modalities: Small molecules (plant-derived)
Industry: Biotech

Drug pipeline

2 assets

tigilanol tiglate

1 more asset in the full pipeline.

Request access →

Partnerships

MSD (partnership for tigilanol tiglate in combination with Keytruda/pembrolizumab)

Beyond the preview

Go deeper on QBiotics Group Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QBiotics Group Limited.

Explore the full profile